Bioscience News - GEG Tech top picks

After 20 months after interrupting antiretroviral therapy, HIV was undetectable in the patient’s blood.

She’s the third person ever to be cured. Researchers announced that the new approach holds the potential for curing more people of racially diverse backgrounds.

A new HIV vaccine candidate has been trialled in humans and monkeys, with promising results.

Nearly 400 healthy, uninfected adults mounted an immune response against the vaccine and tolerated it well, according to the latest study. In monkeys, 67 percent were protected against the closely-related SHIV infection.

The International AIDS Society president has called on the United States to "stay engaged" in HIV research. US President Donald Trump's proposed budget outlined funding cuts for global health initiatives.

For World AIDS Day, a French institute, the IIDSRSI, announced the launch of an anti-HIV medication on the African market. However, the medication in question has not been proven to be effective. The institute is supported by renowned scientists such as Professors Jean Claude Chermann (France) and Mark Wainberg (Canada). This article exposes the underbelly of this trafficking.

A single infusion of antibodies can protect monkeys from infection with a virus that is similar to HIV for nearly six months.

The finding provides further evidence that antibodies — specialized proteins that the body produces to fight infections — could one day be used as a method to prevent people from becoming infected with HIV.

A 53-year-old man in Germany has become at least the third person with HIV to be declared cleared of the virus after a procedure that replaced his bone marrow cells with HIV-resistant stem cells from a donor.

A 36-year-old man in Brazil has seemingly cleared an HIV infection—making him the proof of principle in humans of a novel drug strategy designed to flush the AIDS virus out of all of its reservoirs in the body. After receiving an especially aggressive combination of antiretroviral (ARV) drugs and nicotinamide (vitamin B3), the man, who asks to be referred to as the São Paulo Patient to protect his privacy, went off all HIV treatment in March 2019 and has not had the virus return to his blood.

Suppressive combination antiretroviral therapy fails to eradicate HIV-1 latent reservoirs in poorly characterized cell compartments. Here, urethral macrophages, but not urethral T cells, are shown to contain integrated HIV-1 DNA and to be able to release infectious HIV-1 following reactivation with lipopolysaccharide.

The results of this study show that immunization of cows may provide an avenue to rapidly generate antibody prophylactics and therapeutics to address disease agents that have evolved to avoid human antibody responses.

French researchers have identified a marker that makes it possible to differentiate "dormant" HIV-infected cells from healthy cells. This discovery will make it possible to isolate and analyze reservoir cells which, by silently hosting the virus, are responsible for its persistence even among patients receiving antiviral treatment, whose viral load is undetectable. It offers new therapeutic strategies for targeting infected cells.

HIV research has come a long way since the disease was discovered in the 1980’s. Triple therapy was a major milestone, and now biotech and pharma have shifted their focuses to finding an HIV cure. We’ve scanned the biotech industry and catalogued promising developments in the field.